– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and ...
Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential ...
Esperion ESPR announced that it has signed an amendment to its existing collaboration with Daiichi Sankyo Europe (DSE), which is valued at $125 million. One of the terms of this agreement also ...
"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Ann Arbor-based drug maker Esperion Therapeutics Inc. and ...
Daiichi Sankyo’s DS3610 enters clinical development in patients with advanced solid tumours: Tokyo Wednesday, November 12, 2025, 11:00 Hrs [IST] Daiichi Sankyo, an innovative gl ...
ANN ARBOR, Mich. & MUNICH--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback